Lynne S Newbold
Overview
Explore the profile of Lynne S Newbold including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
194
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Basta N, Berthe A, Keita M, Onwuchekwa U, Tamboura B, Traore A, et al.
J Infect
. 2017 Dec;
76(2):140-148.
PMID: 29197599
Objectives: Carriers of Neisseria meningitidis are a key source of transmission. In the African meningitis belt, where risk of meningococcal disease is highest, a greater understanding of meningococcal carriage dynamics...
2.
Clark S, Lekshmi A, Lucidarme J, Hao L, Tsao H, Lee-Jones L, et al.
J Infect
. 2016 Mar;
73(1):63-70.
PMID: 27025206
Objectives: To compare the distribution of capsular groups and factor H-binding protein (fHBP) variants among meningococcal isolates and non-culture clinical specimens and to assess the representativeness of group B isolates...
3.
Hill D, Lucidarme J, Gray S, Newbold L, Ure R, Brehony C, et al.
Lancet Infect Dis
. 2015 Oct;
15(12):1420-8.
PMID: 26515523
Background: Invasive meningococcal disease (IMD) is a worldwide health issue that is potentially preventable with vaccination. In view of its sporadic nature and the high diversity of Neisseria meningitidis, epidemiological...
4.
Clark S, Lucidarme J, Newbold L, Borrow R
PLoS One
. 2014 Mar;
9(2):e89921.
PMID: 24587125
Factor H-Binding Protein (fHbp) is an outer membrane protein antigen included in two novel meningococcal group B vaccines and, as such, is an important typing target. Approximately 50% of meningococcal...
5.
Lucidarme J, Gilchrist S, Newbold L, Gray S, Kaczmarski E, Richardson L, et al.
Clin Vaccine Immunol
. 2013 Jun;
20(9):1360-9.
PMID: 23803905
The poor immunogenicity of the meningococcal serogroup B (MenB) capsule has led to the development of vaccines targeting subcapsular antigens, in particular the immunodominant and diverse outer membrane porin, PorA....
6.
Ladhani S, Flood J, Ramsay M, Campbell H, Gray S, Kaczmarski E, et al.
Vaccine
. 2012 Mar;
30(24):3710-6.
PMID: 22429756
A number of meningococcal vaccines have either been recently licensed or are in late-phase clinical trials. To inform national vaccination policy, it is important to define the burden of disease...
7.
Ladhani S, Lucidarme J, Newbold L, Gray S, Carr A, Findlow J, et al.
Emerg Infect Dis
. 2012 Jan;
18(1):63-70.
PMID: 22261040
Enhanced national surveillance for invasive meningococcal disease in England and Wales identified an increase in laboratory-confirmed capsular group Y (MenY) disease from 34 cases in 2007 to 44 in 2008...
8.
Lucidarme J, Newbold L, Findlow J, Gilchrist S, Gray S, Carr A, et al.
Clin Vaccine Immunol
. 2010 Dec;
18(2):194-202.
PMID: 21123522
In 2007, recommendations were proposed for the molecular typing of meningococci. Multilocus sequence typing (MLST) was recommended to guide national and international disease management and facilitate studies of population biology...
9.
Kwan P, Birtles A, Bolton F, French N, Robinson S, Newbold L, et al.
Appl Environ Microbiol
. 2008 Apr;
74(12):3626-33.
PMID: 18424539
Multilocus sequence typing (MLST), an accurate and phylogenetically robust characterization method for population studies of Campylobacter, was applied to Campylobacter jejuni isolates (n = 297) from the fecal samples of...